Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Clene (CLNN) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for Clene (CLNN) over the last 6 years, with Q3 2025 value amounting to $2.7 million.

  • Clene's Gains from Investment Securities rose 4142.78% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 4142.78%. This contributed to the annual value of $1.9 million for FY2024, which is 7798.91% up from last year.
  • Clene's Gains from Investment Securities amounted to $2.7 million in Q3 2025, which was up 4142.78% from $2.3 million recorded in Q2 2025.
  • Over the past 5 years, Clene's Gains from Investment Securities peaked at $16.2 million during Q1 2023, and registered a low of -$6.3 million during Q3 2023.
  • For the 5-year period, Clene's Gains from Investment Securities averaged around $3.5 million, with its median value being $1.8 million (2024).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first soared by 2644397.56% in 2022, then tumbled by 50939.95% in 2024.
  • Clene's Gains from Investment Securities (Quarter) stood at $400000.0 in 2021, then surged by 2943.39% to $12.2 million in 2022, then plummeted by 103.11% to -$379000.0 in 2023, then soared by 537.47% to $1.7 million in 2024, then soared by 61.73% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $2.3 million for Q2 2025, and $2.3 million during Q1 2025.